| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 4.0K | 18.7% | 17.2% |
| Total Income | 4.1K | 17.0% | 15.7% |
| Expenditure | 3.2K | 16.7% | 15.9% |
| PBT | 895.83 | 16.2% | 14.8% |
| Net Profit | 779.11 | 16.6% | 11.0% |
| OPM | 23.01% | 0.70pp | 7.23pp |
| NPM | 18.98% | 0.06pp | 0.80pp |
| EPS | 63.99 | 15.2% | 11.1% |
Alkem Laboratories Announces Q2 and H1 Financial Results for FY2025-2026
13 Nov 2025 · 13 Nov 2025, 01:52 pm
Summary
Alkem Laboratories has announced its Q2 and H1 financial results for the fiscal year 2025-2026. The results were reviewed by Deloitte Haskins & Sells LLP. The company has several subsidiaries, some of which were not reviewed by their auditors. The interim financial information of these subsidiaries is not material to the Group.
Key Highlights
- 1
Q2 and H1 financial results for FY2025-2026 announced
- 2
Results reviewed by Deloitte Haskins & Sells LLP
- 3
Several subsidiaries, some not reviewed by their auditors
- 4
Interim financial information of these subsidiaries not material to the Group
Informational and educational content only. Not investment advice.